

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number  
**WO 03/035081 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/663**,  
31/635, 31/444, 31/42, 31/365, 31/337, 31/196, 45/06,  
A61P 29/00, 35/00 // (A61K 31/663, 31:635) (A61K  
31/663, 31:635, 31:337) (A61K 31/663, 31:337) (A61K  
31/635, 31:337)

(21) International Application Number: PCT/EP02/11696

(22) International Filing Date: 18 October 2002 (18.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/345,921 19 October 2001 (19.10.2001) US

(71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1235 Vienna (AT).

(71) Applicants and

(72) Inventors: **LIPTON, Allan** [US/US]; Penn State College of Medicine, 500 University Drive, Hershey, PA 17033 (US). **WITTERS, Lois, Mary** [US/US]; 25 Fisher Road, York Haven, PA 17370 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **GREEN, Jonathan** [GB/CH]; Waldstrasse 12, CH-4144 Arlesheim (CH).

(74) Agent: **GROS, Florent**; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITION FOR USE FOR THE TREATMENT OF MALIGNANCIES COMPRISING IN COMBINATION A BISPHOSPHONATES, A COX-2 INHIBITOR AND A TAXOL

(57) Abstract: A pharmaceutical composition for treatment of malignancies, in particular a malignant disease which is associated with the development of bone metastases or excessive bone resorption, comprises in combination a bisphosphonates, COX-2 inhibitor and/or a taxol or derivative thereof for simultaneous, sequential or separate use. Also provided is a method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonates, an effective amount of a COX-2 inhibitor and/or an effective amount of a taxol or derivative thereof.



**WO 03/035081 A1**